BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 9469371)

  • 1. 1997 update of recommendations for the use of tumor markers in breast and colorectal cancer. Adopted on November 7, 1997 by the American Society of Clinical Oncology.
    J Clin Oncol; 1998 Feb; 16(2):793-5. PubMed ID: 9469371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology.
    Bast RC; Ravdin P; Hayes DF; Bates S; Fritsche H; Jessup JM; Kemeny N; Locker GY; Mennel RG; Somerfield MR;
    J Clin Oncol; 2001 Mar; 19(6):1865-78. PubMed ID: 11251019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. Adopted on May 17, 1996 by the American Society of Clinical Oncology.
    J Clin Oncol; 1996 Oct; 14(10):2843-77. PubMed ID: 8874347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. American Society of Clinical Oncology 1998 update of recommended breast cancer surveillance guidelines.
    Smith TJ; Davidson NE; Schapira DV; Grunfeld E; Muss HB; Vogel VG; Somerfield MR
    J Clin Oncol; 1999 Mar; 17(3):1080-2. PubMed ID: 10071303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recommended colorectal cancer surveillance guidelines by the American Society of Clinical Oncology.
    Desch CE; Benson AB; Smith TJ; Flynn PJ; Krause C; Loprinzi CL; Minsky BD; Petrelli NJ; Pfister DG; Somerfield MR
    J Clin Oncol; 1999 Apr; 17(4):1312. PubMed ID: 10561194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recommended breast cancer surveillance guidelines. American Society of Clinical Oncology.
    J Clin Oncol; 1997 May; 15(5):2149-56. PubMed ID: 9164230
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. Adopted on May 16, 1997 by the American Society of Clinical Oncology.
    J Clin Oncol; 1997 Aug; 15(8):2996-3018. PubMed ID: 9256144
    [TBL] [Abstract][Full Text] [Related]  

  • 8. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer.
    Harris L; Fritsche H; Mennel R; Norton L; Ravdin P; Taube S; Somerfield MR; Hayes DF; Bast RC;
    J Clin Oncol; 2007 Nov; 25(33):5287-312. PubMed ID: 17954709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA).
    Giovanella L; Ceriani L; Giardina G; Bardelli D; Tanzi F; Garancini S
    Clin Chem Lab Med; 2002 Mar; 40(3):298-303. PubMed ID: 12005221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. American Society of Clinical Oncology technology assessment on breast cancer risk reduction strategies: tamoxifen and raloxifene.
    Chlebowski RT; Collyar DE; Somerfield MR; Pfister DG
    J Clin Oncol; 1999 Jun; 17(6):1939-55. PubMed ID: 10561236
    [TBL] [Abstract][Full Text] [Related]  

  • 11. American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel.
    Hillner BE; Ingle JN; Berenson JR; Janjan NA; Albain KS; Lipton A; Yee G; Biermann JS; Chlebowski RT; Pfister DG
    J Clin Oncol; 2000 Mar; 18(6):1378-91. PubMed ID: 10715310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Postmastectomy radiotherapy: clinical practice guidelines of the American Society of Clinical Oncology.
    Recht A; Edge SB; Solin LJ; Robinson DS; Estabrook A; Fine RE; Fleming GF; Formenti S; Hudis C; Kirshner JJ; Krause DA; Kuske RR; Langer AS; Sledge GW; Whelan TJ; Pfister DG;
    J Clin Oncol; 2001 Mar; 19(5):1539-69. PubMed ID: 11230499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition.
    Chlebowski RT; Col N; Winer EP; Collyar DE; Cummings SR; Vogel VG; Burstein HJ; Eisen A; Lipkus I; Pfister DG;
    J Clin Oncol; 2002 Aug; 20(15):3328-43. PubMed ID: 12149307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Standards, options and recommendations for tumor markers in colorectal cancer].
    Eche N; Pichon MF; Quillien V; Gory-Delabaere G; Riedinger JM; Basuyau JP; Daver A; Buecher B; Conroy T; Dieu L; Bidart JM; Deneux L;
    Bull Cancer; 2001 Dec; 88(12):1177-206. PubMed ID: 11792611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer.
    Locker GY; Hamilton S; Harris J; Jessup JM; Kemeny N; Macdonald JS; Somerfield MR; Hayes DF; Bast RC;
    J Clin Oncol; 2006 Nov; 24(33):5313-27. PubMed ID: 17060676
    [TBL] [Abstract][Full Text] [Related]  

  • 16. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers.
    Sturgeon CM; Duffy MJ; Stenman UH; Lilja H; Brünner N; Chan DW; Babaian R; Bast RC; Dowell B; Esteva FJ; Haglund C; Harbeck N; Hayes DF; Holten-Andersen M; Klee GG; Lamerz R; Looijenga LH; Molina R; Nielsen HJ; Rittenhouse H; Semjonow A; Shih IeM; Sibley P; Sölétormos G; Stephan C; Sokoll L; Hoffman BR; Diamandis EP;
    Clin Chem; 2008 Dec; 54(12):e11-79. PubMed ID: 19042984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The ASCO experience with evidence-based clinical practice guidelines.
    Smith TJ; Somerfield MR
    Oncology (Williston Park); 1997 Nov; 11(11A):223-7. PubMed ID: 9430192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology.
    Schiffer CA; Anderson KC; Bennett CL; Bernstein S; Elting LS; Goldsmith M; Goldstein M; Hume H; McCullough JJ; McIntyre RE; Powell BL; Rainey JM; Rowley SD; Rebulla P; Troner MB; Wagnon AH;
    J Clin Oncol; 2001 Mar; 19(5):1519-38. PubMed ID: 11230498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002.
    Winer EP; Hudis C; Burstein HJ; Chlebowski RT; Ingle JN; Edge SB; Mamounas EP; Gralow J; Goldstein LJ; Pritchard KI; Braun S; Cobleigh MA; Langer AS; Perotti J; Powles TJ; Whelan TJ; Browman GP
    J Clin Oncol; 2002 Aug; 20(15):3317-27. PubMed ID: 12149306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and the American Society of Clinical Oncology.
    Sepulveda AR; Hamilton SR; Allegra CJ; Grody W; Cushman-Vokoun AM; Funkhouser WK; Kopetz SE; Lieu C; Lindor NM; Minsky BD; Monzon FA; Sargent DJ; Singh VM; Willis J; Clark J; Colasacco C; Rumble RB; Temple-Smolkin R; Ventura CB; Nowak JA
    J Clin Oncol; 2017 May; 35(13):1453-1486. PubMed ID: 28165299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.